Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Integra Lifesciences Holdings (IART) Work In Process (2016 - 2017)

Integra Lifesciences Holdings' Work In Process history spans 7 years, with the latest figure at $47.3 million for Q3 2017.

On a quarterly basis, Work In Process changed N/A to $47.3 million in Q3 2017 year-over-year; TTM through Sep 2017 was $47.3 million, a N/A change, with the full-year FY2016 number at $50.0 million, changed N/A from a year prior.
Work In Process hit $47.3 million in Q3 2017 for Integra Lifesciences Holdings, down from $50.0 million in the prior quarter.
Over the last five years, Work In Process for IART hit a ceiling of $54.7 million in Q2 2015 and a floor of $47.3 million in Q3 2017.
Historically, Work In Process has averaged $50.5 million across 4 years, with a median of $50.1 million in 2014.